Price T Rowe Associates Inc Merus N.V. Transaction History
Price T Rowe Associates Inc
- $867 Billion
- Q4 2024
A detailed history of Price T Rowe Associates Inc transactions in Merus N.V. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,116,820 shares of MRUS stock, worth $52.9 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,116,820
Previous 1,281,980
12.88%
Holding current value
$52.9 Million
Previous $64 Million
26.68%
% of portfolio
0.01%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding MRUS
# of Institutions
202Shares Held
60.7MCall Options Held
111KPut Options Held
85.7K-
Rtw Investments, LP New York, NY4.17MShares$198 Million2.86% of portfolio
-
Commodore Capital LP New York, NY3.87MShares$184 Million16.32% of portfolio
-
Wellington Management Group LLP Boston, MA3.5MShares$166 Million0.03% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY2.97MShares$141 Million3.1% of portfolio
-
Samlyn Capital, LLC New York, NY2.67MShares$126 Million1.81% of portfolio
About Merus N.V.
- Ticker MRUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,878,200
- Market Cap $2.17B
- Description
- Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...